Dual targeted therapy for the management of inflammatory bowel disease

doi:10.3877/cma.j.issn.2095-2015.2023.02.001

Abstract

Abstract:

Inflammatory bowel disease(IBD)is a chronic, recurrent inflammatory bowel disease with unknown etiology.With the emergence of new therapies such as biologics and small molecule drugs(SMDs), the therapeutic effect of IBD has improved greatly, but there are still some patients with difficulty in treatment.In recent years, dual targeted therapy, which is the combination of biologics and/or SMDs, for patients with refractory IBD has been explored at home and abroad.In this paper, we will discuss the definition, efficacy, safety and suitable population of dual targeted therapy.

Key words: Inflammatory bowel disease, Dual targeted therapy, Efficacy, Safety

Wensong Ge. Dual targeted therapy for the management of inflammatory bowel disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 65-67.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2023.02.001

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2023/V13/I02/65

References 15

1	Katsanos KH，Papamichael K，Feuerstein JD，et al.Biological therapies in inflammatory bowel disease：beyond anti-TNF therapies[J]．Clin Immunol，2019，206：9-14.
2	Rawla P，Sunkara T，Raj JP.Role of biologics and biosimilars in inflammatory bowel disease：current trends and future perspectives[J]．J Inflamm Res，2018，11：215-226.
3	Na SY，Moon W．Perspectives on current and novel treatments for inflammatory bowel disease[J]．Gut Liver，2019，13(6)：604-616.
4	Neurath MF.Current and emerging therapeutic targets for IBD[J]．Nat Rev Gastroenterol Hepatol，2017，14(5)：269-278.
5	Haider M，Lashner B．Dual Targeted Therapy for the Management of Inflammatory Bowel Disease[J]．J Clin Gastroenterol，2021，55(8)：661-666.
6	Roblin X，Paul S，Ben-Horin S．Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy[J]．J Crohns Colitis，2018，12(3)：379-380.
7	Buer LCT，Høivik ML，Warren DJ，et al.Combining anti-TNFαand vedolizumab in the treatment of inflammatory bowel disease：a case series[J]．Inflamm Bowel Dis，2018，24(5)：997-1004.
8	Glassner K，Oglat A，Duran A，et al.The use of combination biological or small molecule therapy in inflammatory bowel disease：a retrospective cohort study[J]．J Dig Dis，2020，21(5)：264-271.
9	Sands BE，Kozarek R，Spainhour J，et al.Safety and tolerability of concurrent natalizumab treatment for patients with Crohn′s disease not in remission while receiving infliximab[J]．Inflamm Bowel Dis，2007，13(1)：2-11.
10	Hirten RP，Iacucci M，Shah S，et al.Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders[J]．Clin Gastroenterol Hepatol，2018，16(9)：1374-1384.
11	Kwapisz L，Raffals LE，Bruining DH，et al.Combination biologic therapy in inflammatory bowel disease：experience from a tertiary care center[J]．Clin Gastroenterol Hepatol，2020，19(3)：616-617.
12	Yang E，Panaccione N，Whitmire N，et al.Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn′s disease[J]．Aliment Pharmacol Ther，2020，51(11)：1031-1038.
13	Volk N，Siegel CA.Defining failure of medical therapy for inflammatory bowel disease[J]．Inflamm Bowel Dis，2019，25(1)：74-77.
14	Privitera G，Onali S，Pugliese D，et al.Dual targeted therapy：a possible option for the management of refractory inflammatory bowel disease[J]．J Crohns Colitis，2020，15：335-339.
15	Yzet C，Dupas J-LL，Fumery M．Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease[J]．Am J Gastroenterol，2016，111(5)：748-749.

[1]	Jinglong He, Hongxi Shang, Min Hao, Wei Xie, Minghong Gao, Wei Sun, Anqing Liu. Clinical effect of multiple joints replacements in patients with severe rheumatoid arthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 860-864.
[2]	Hua Zhang, Yu Sun, Shijian Xiang, Yingmei Li, Xiaoqun Wang. Research on chemosensitivity evaluation using circulating tumor cells in advanced gastrointestinal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 422-425.
[3]	Haiqin Tang, Xiuzhi Guo, Xiaosu Zhu, Shidi Zhao. Clinical safety study of "tunnel method" laparoscopic anatomic left hemihepatectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 674-677.
[4]	Qingqing Zhu, Zhenqi Wei. Application value of self-efficacy management during perioperative period in patients with inguinal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 773-777.
[5]	Jun Liu, Ji Zhu, Jun Yin. Anesthesia effect and safety of dexmedetomidine in inguinal hernia surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(05): 570-573.
[6]	Fengjie Wang, Liguang Wang, Shan Liao, Ying Liu, Rongdang Fu, Huanwei Chen. Safety and efficacy of laparoscopic right hemihepatectomy for hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 517-522.
[7]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[8]	Heya Na, Dan Zhu. Effect of red-light therapy in myopia control in children [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(04): 252-256.
[9]	Lijiao Jiang, Feng Zhang, Yuping Zhou. Clinical efficacy observation of treating elderly patients with acute non-variceal upper gastrointestinal hemorrhage using the MDT model [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 520-524.
[10]	Wenlong Liang, Jie Cao, Qing Huang, Yong Lin, Hongli Huang, Ping Yang, Guanwei Li, He Hu. Efficacy and safety analysis of sintilimab combined with regofenib in the treatment of advanced colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 409-413.
[11]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Maintaining vigilance in the differential diagnosis of inflammatory bowel disease and rare bowel disorders [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 273-276.
[12]	Jingxu Zhang, Defang Li, Shangke You, Yutian Zhang. Clinical efficacy of bevacizumab and anlotinib combined with oxaliplatin in the treatment of advanced rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 289-293.
[13]	Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[14]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.
[15]	Wenxi Cao, Xiao Chen, Laifa Zhu, Yongping Zhou. Efficacy and safety of nituzumab combined with albumin bound paclitaxel in treatment of pancreatic cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 409-413.

Please choose a citation manager

Content to export